MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, announced today that it will collaborate with Neugenesis Corporation, a biotechnology company developing complex protein biotherapeutics, to develop technologies for the rapid manufacturing of vaccines and drugs. The SRI-awarded subcontract is part of a major contract awarded to Neugenesis by the Defense Advanced Research Projects Agency (DARPA).
